<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Korro Bio, Inc. — News on 6ix</title>
<link>https://6ix.com/company/frequency-therapeutics-inc</link>
<description>Latest news and press releases for Korro Bio, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 27 May 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/frequency-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358ec978dffbe2df1015c0.webp</url>
<title>Korro Bio, Inc.</title>
<link>https://6ix.com/company/frequency-therapeutics-inc</link>
</image>
<item>
<title>Korro to Present at the 2026 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-to-present-at-the-2026-jefferies-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-to-present-at-the-2026-jefferies-global-healthcare-conference</guid>
<pubDate>Wed, 27 May 2026 04:00:00 GMT</pubDate>
<description>Korro to Present at the 2026 Jefferies Global Healthcare Conference</description>
</item>
<item>
<title>Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-selects-krro-111-as-development-candidate-for-the-potential-treatment-of-alpha-1-antitrypsin-deficiency-aatd</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-selects-krro-111-as-development-candidate-for-the-potential-treatment-of-alpha-1-antitrypsin-deficiency-aatd</guid>
<pubDate>Tue, 19 May 2026 04:00:00 GMT</pubDate>
<description>Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver</description>
</item>
<item>
<title>Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-first-quarter-2026-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-first-quarter-2026-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 07 May 2026 11:00:00 GMT</pubDate>
<description>Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing for KRRO-121 expected in the second half of 2026Advanced early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD); on track to announce development candidate in second quarter of 20</description>
</item>
<item>
<title>Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-announces-oral-and-poster-presentations-at-upcoming-scientific-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-announces-oral-and-poster-presentations-at-upcoming-scientific-conferences</guid>
<pubDate>Thu, 16 Apr 2026 11:30:00 GMT</pubDate>
<description>American Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference3rd International Conference on Ureagenesis Defects and Allied ConditionsEuropean Association for the Study of the Liver (EASL) Congress 2026 CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent dise</description>
</item>
<item>
<title>Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 10 Apr 2026 20:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 15,000 shares of Korro’s common stock at an exercise price of $13.46 per share, the closing price per share of Korro</description>
</item>
<item>
<title>Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharma</description>
</item>
<item>
<title>Korro Announces Oversubscribed $85 Million Private Placement</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-announces-oversubscribed-dollar85-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-announces-oversubscribed-dollar85-million-private-placement</guid>
<pubDate>Mon, 09 Mar 2026 11:30:00 GMT</pubDate>
<description>Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs including reporting clinical data for: KRRO-121 for hyperammonemia in patients with urea cycle disordersKorro’s GalNAc-conjugated oligonucleotide intended for patients with alpha-1 antitrypsin deficiency Company expects proceeds to extend cash runway into the second half of 2028 CAMBRIDG</description>
</item>
<item>
<title>Korro to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar’s presentation will take place on Tu</description>
</item>
<item>
<title>Korro to Host Virtual Analyst Day on January 27, 2026</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-host-virtual-analyst-day-130000454</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-host-virtual-analyst-day-130000454</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro</description>
</item>
<item>
<title>Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-present-44th-annual-j-130000744</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-present-44th-annual-j-130000744</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the “Event</description>
</item>
<item>
<title>Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-third-quarter-financial-210500954</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-third-quarter-financial-210500954</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients —KRRO-110 did not reach projected levels of functional protein following a single administration —Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026 —Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia —Reports t</description>
</item>
<item>
<title>Korro to Participate in Upcoming Investor and Scientific Conferences</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-participate-upcoming-investor-scientific-203000368</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-participate-upcoming-investor-scientific-203000368</guid>
<pubDate>Tue, 02 Sep 2025 20:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: Citi's 2025 Biopharma Back to School ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025. Cantor Global Healthcare Con</description>
</item>
<item>
<title>Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-second-quarter-2025-110000514</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-second-quarter-2025-110000514</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro’s rare m</description>
</item>
<item>
<title>Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-receives-european-medicines-agency-120000604</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-receives-european-medicines-agency-120000604</guid>
<pubDate>Mon, 21 Jul 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro’s investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency</description>
</item>
<item>
<title>Korro to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-participate-upcoming-investor-conferences-200500920</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-participate-upcoming-investor-conferences-200500920</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will pres</description>
</item>
<item>
<title>Korro Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-first-quarter-2025-203000085</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-first-quarter-2025-203000085</guid>
<pubDate>Wed, 07 May 2025 20:30:00 GMT</pubDate>
<description>—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027 —Second development candidate expected to be announced in 2025 —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketab</description>
</item>
<item>
<title>Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-appoints-biotech-industry-veteran-113000683</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-appoints-biotech-industry-veteran-113000683</guid>
<pubDate>Tue, 01 Apr 2025 11:30:00 GMT</pubDate>
<description>Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting OfficerCAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, anno</description>
</item>
<item>
<title>Korro Reports Full Year 2024 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-full-2024-financial-110000360</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-reports-full-2024-financial-110000360</guid>
<pubDate>Tue, 18 Mar 2025 11:00:00 GMT</pubDate>
<description>—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan Drug Designation to KRRO-110 for the treatment of AATD —Executing 3-2-1 strategy through end of 2027 with the goal of establishing three clinical-stage development programs, targeting two tissue types with a single RNA-editing platform; Second development candi</description>
</item>
<item>
<title>KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/krro-110-receives-orphan-drug-120000852</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/krro-110-receives-orphan-drug-120000852</guid>
<pubDate>Fri, 14 Mar 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). “Receiving orphan drug designation from t</description>
</item>
<item>
<title>Korro to Present at the TD Cowen 45th Annual Health Care Conference</title>
<link>https://6ix.com/company/frequency-therapeutics-inc/news/korro-present-td-cowen-45th-130000036</link>
<guid isPermaLink="true">https://6ix.com/company/frequency-therapeutics-inc/news/korro-present-td-cowen-45th-130000036</guid>
<pubDate>Wed, 26 Feb 2025 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief</description>
</item>
</channel>
</rss>